$BRKR

Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.

Pusch Wolfgang (President BMID Group) sold 3,473 shares of BRUKER CORP (BRKR) at $56.90 ($0.20M total) on 2026-08-17.

Bruker (BRKR) reported Q2 sales of $838.5M and a net loss of $52M. It cut 2026 revenue guidance to $3.54B-$3.57B and recorded $134.9M in goodwill and intangible impairments. Bruker expanded its AI lab collaboration with Atinary, including a minority stake, to build AI-driven Self-Driving Labs using Chemspeed, FT-NMR and SciY software.

Bruker Corporation (BRKR) said its board declared a quarterly cash dividend of $0.05 per common share ($0.01 par). The dividend was declared Aug. 14, 2026, with a record date of Sept. 21, 2026 and a payment date of Oct. 7, 2026, for shareholders of record then.

Bruker (BRKR) reported Q2 2026 revenue of $838.5 million, up 5.2% year over year, with organic growth of 2.8% (3.4% excluding U.S. tariff refund impacts). Non-GAAP gross margin was 52.1% and non-GAAP EPS $0.49. FY2026 guidance: revenue $3.54B to $3.57B and non-GAAP EPS $2.10 to $2.15.

Bruker (Nasdaq: BRKR) announced an expanded strategic collaboration with Atinary Technologies to integrate Atinary’s SDLabs self-driving lab platform with Chemspeed automation, Bruker instruments, and SciY software for closed-loop, agentic AI-driven R&D. Bruker also made a minority investment in Atinary; financial terms were not disclosed.

Bruker reported Q2 revenue of $838.5M vs $854.8M estimates and adjusted EPS of $0.49 vs $0.38, with management citing weak U.S. academic and government funding and deep-tech delivery timing delays. It cut full-year revenue guidance to $3.56B midpoint and reiterated adjusted EPS of $2.13. Margin was -7.8%.

Simply Wall St reports Bruker (BRKR) drew investor attention after Q2 results showed rising sales but a net loss tied largely to impairment charges. The article cites 2026 revenue guidance, a 25.91% 90-day share return, and a consensus fair value of $59.75 versus a $56.32 close, with analyst targets ranging from $40 to $70.

Bruker (NASDAQ:BRKR) reported Q2 2026 revenue of $838.5M, up 5.2% (organic growth 2.8%). Scientific Instruments bookings rose 10% organically with a book-to-bill above 1.0x. Non-GAAP EPS increased to $0.49; GAAP results included a non-cash goodwill impairment. Bruker kept 2026 non-GAAP EPS guidance at $2.10-$2.15 and updated revenue guidance to $3.54B-$3.57B for currency and tax effects.

US stock indices rose to record highs as investors weighed strong Q2 tech earnings expectations. Bloomberg Intelligence projects Q2 earnings up about 23% for S&P 500, with 86% of 322 reporters beating estimates. Markets priced a 59% chance of a 25 bp Fed hike and 85% for an ECB hike. SOX and AI chip stocks led; oil fell and energy stocks lagged.